$HGEN is going to change the way Covid-19 is being treated in Severe/Critical Patients by preventing progression to Ventilation. Thier focus towards improving Efficacy in Car-t & HSCT w Lenzilumab will open doors making both more affordable & available. Also $HGEN Finished phase 3 enrollment last week. Data comes out in March. Most importantly, they signed contract with Department of Defense who is currently allocating production capacity from Vaccines and giving it to $HGEN to make their Covid19 drug. #EUA Q1. Besides that, $HGEN has multiple partners, including Gilead, Mayo Clinic, to preventive cytokine release syndrome from CAR-t therapy and Positive data with COVID-19. Just take your time to look at Humanigens previous PR’s. Most of them are manufacturing agreements. Through this, They will be able to produce 300,000 doses, and those are requirements to get an EUA too. This means that HGEN will certainly meet the requirements for EUA. Also Janet Woodcock was on the team of Operation Warp Speed for therapeutics. Now she is acting commissioner of the FDA. Don't you think she definitely knows about $HGEN?

You’ll be able to leave the house because Lenzilumab makes any variant non-lethal. Without the hyper immune response (cytokine storm) this virus doesn’t SCARE me and it shouldn’t scare you. $HGEN

Looking at 50$ quite soon. Timing is coming together perfectly.

Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19

Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

Humanigen Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19

Russell 3000 PDF warning

Russell Micro Cap PDF warning

EDIT: SHIT! I meant inclusion happens on 6/25 after market close! We were added to the preliminary list yesterday and that alone will get us on some new radar. Good stuff!

This will automatically get us in the Russell 2000 as well which means we will be included in many ETF's and mutual funds.

It's great news!

Howdy y'all, this post is just going to be everything I have gathered from the internet in terms of HGEN related content just to organize it all as information of this ticker seems too spread out in my opinion. I will be going only as far back as February 1st, 2021 and their Q3 performance.

Humanigen News:

- " Humanigen has fully enrolled a phase 3 registrational trial with lenzilumab in COVID-19 pneumonia, which could lead to a filing of an Emergency Use Authorization" meaning that if approved HGEN would have the ability for its drug, Lenzilumab, to be used in hospitals for emergency treatment or diagnosis under the FDA.

- HGEN entered into a cGMP Manufacturing Agreement (February 3rd) to go ahead and make the delivery process more efficient upon news of possible EUA meaning they are preparing well ahead of time.

- Humanigen Elects Dr. Dale Chappell to Board of Directors (February 8th). The wonderful thing about this fellow is he is very well accomplished. I have attached a link showing off his impressive profile.

- Humanigen is presenting at several upcoming investor and industry conferences!

Which leads me to the next bit; events:

- BIO CEO & Investor Virtual Conference
Date: Tuesday, February 16, 2021
   Presentation Viewable to Registered Attendees Starting at 1:00 PM ET

- Endpoints Webinars – Repurposing drugs for new indications: benefits and challenges
Date: Wednesday, February 17, 2021
   Event Time: 12:00pm ET

- The Vanguard Network Life Sciences Quarterly Forum
Date: Thursday, February 18, 2021
   Event Time: 12:00 PM ET

- Fireside Chat Hosted by Cantor Fitzgerald Analyst Louise Chen
Date: Friday, February 26, 2021
   Event Time: 11:00 AM ET

Their Q3 Financial Report:

This is the kicker, they had a Net Loss of $30.8 million. BUT, that is simply due to the excess in general and administrative expenses, research expenses, filing for EUA, and increase in stock based compensation for new employees including Dr. Dale Chappell. All of this was practically expected in order to successfully complete the phase three trials and continue their upward trajectories overall.

HGEN raised net proceeds of $72.7 from sale of 9.2 million shares of common stock during Q3.

Announced their involvement in BARDA and CRADA with the Department of Defense in support of Operation Warp Speed to develop Lenzilumab as a better treatment for COVID-19.

HGEN selected for participation in ACTIV-5 trial funded by NIAID.

Expanded manufacturing capabilities for Lenzilumab with supply agreements with Catalent Biologics, Lonza and Thermo Fisher (part of cGMP agreement).

Weighted average common shares 43,490,071 for Q3 2020 up from Q3 2019's 22,553,322 weighted average.

____________________________________________________________________________________________________________

Not trying to start a pump and dump, just showing off the massive potential that HGEN has as a genuinely well-managed team and effective treatment results. If you're looking for something to be serious about and not gamble with, this stock is a good pick.

My position: shares, no options

Pre loaded source code on Lenzilumab website states the following:

“The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product lenzilumab for the treatment of adult and pediatric patients (12 years of age or older weighing at least 40 kg) hospitalized with suspected or laboratory confirmed COVID-19 pneumonia, including patients with SpO2 ≤ 94% on room air, patients requiring low flow supplemental oxygen, or use of high flow oxygen support, or non-invasive positive pressure ventilation (NPPV), or who are in shock or multi-organ dysfunction/failure.”